活检组和对照组患者1、3、5年无复发生存率(recurrence-free survival,RFS)分别为96.3％与85.4％(x2=14.955,P＜0.001)、85.2％与69.8％ (x2=13.183,P＜0.001)、69.9％与64.1％(x2=1.574,P=0.245),无进...
基于10个网页-相关网页
... 况，结合患者的临床病理学特征及随访资料，对患者的术后总生存(Overall survival，OS)和无复发生存(Recurrence-free survival，RFS)进行单因素Kaplan-Meier生存分析及多因素Cox回归分析。
基于4个网页-相关网页
... 况，结合患者的临床病理学特征及随访资料，对患者的术后总生存(Overall survival，OS)和无复发生存(Recurrence-free survival，RFS)进行单因素Kaplan-Meier生存分析及多因素Cox回归分析。
基于4个网页-相关网页
Results Four-year overall survival rates were 58%;recurrence-free survival rates were 49%.
结果515例肝癌患者的4年总生存率为58%,无瘤生存率为49%。
参考来源 - 早期肝癌复发与生存预测标记物的评价·2,447,543篇论文数据，部分数据来源于NoteExpress
Thus, patients with RCC who received vitespen after nephrectomy showed no increased recurrence-free survival.
因此，长期存活的肾切除术后接受噬菌体接种的肾细胞癌病人显示复发率并未增高。
In both groups, overall 5-year survival rate was approximately 70% and recurrence-free survival rate was about 62%.
两组患者的5年总的生存率都接近70%以及无复发的生存率大约为62%。
RESULTS: The candidates' overall 3-year survival rate and recurrence-free survival rate were 67% and 70% after transplantation, respectively.
结果：在移植后，候选人全部3年存活率和无肿瘤复发存活率分别为67％、70％。
应用推荐